. 2011 May 16;13(4):563–568. doi: 10.1038/aja.2010.124

Table 1. Summary of contemporary Korean data on LOH and ART.

Study	Patient No.	Study design	Testosterone preparation	Indication and normal cutoff of patient	Questionnaire used	Methodology of testosterone measurement	Time of testosterone measurement	Complication of testosterone replacement
Hong and Ahn (2002)¹²	28	Non-control prospective trial	Oral TU 160 mg for 3 weeks, then 80 mg up to 3 months	LOH symptom2.8 ng ml⁻¹ (T)13 pg ml⁻¹ (FT)	ADAM	RIA	9–11 a.m.	No significant adverse event
Park et al. (2003)¹³	39	Placebo-controlled prospective trial	Oral TU 160 mg for 3 months	LOH symptom400 ng ml⁻¹ (T)	ADAMPNUHQoL	RIA	—	No dropout
Seo et al. (1998)¹⁴	21	Non-control prospective trial	Non-scrotal transdermal patch (5 mg) for 16 weeks	ED3.0 ng ml⁻¹ (T)Age over 40 years	—	RIA	—	Dropout 22%Skin irritation 4
Bae et al. (2005)¹⁶	135	Retrospective observatory trial	Oral TU 160 mg, then increase dosage	LOH symptom2.55 ng ml⁻¹ (T)Age over 50 years	—	—	9–10 a.m.	—
Park et al. (1999)¹⁸	56	Placebo-controlld prospective trial	Non-scrotal transdermal patch (12.2 mg) for 3 weeks	ED500 mg dl⁻¹ (T)Age over 55 years	PNUHQoL	—	—	Dropout 25% due to skin reactionSkin rash in 64.2%
Park et al. (2007)³⁴	87	Non-control prospective open label multicentre study	Testosterone gel (50 mg) for 12 weeks	LOH symptom350 ng dl⁻¹ (T)73.5 pg ml⁻¹ (FT)	AMS	—	8–11 a.m.	Nine complicationsAcne: 3Itching sense: 2PSA rising :1Voiding dysfunction :1Nocturia : 1-Hot flushing : 1
Bae et al. (2006)³⁵	73	Retrospective trial	Testosterone gel (50 mg) over 3 months	LOH symptom3.5 ng ml⁻¹ (T)	AMS	—	9–10 a.m.	No severe systemic adverse event
Bae et al. (2008)³⁸	33	Non-control prospective trial	TU 1000 mg IM	LOH symptom3.5 ng ml⁻¹ (T)Age over 40 years	AMSIPSS	—	9–11 a.m.	No adverse eventNo dropout
Moon et al. (2010)³⁹	133	Non-control prospective multicentre study	TU 1000 mg IM	LOH symptom3.5 ng ml⁻¹	AMSIIEFGEQ	—	7–11 a.m.	Eight adverse events: dyspnea, hot flushing, acne, gynecomastiaDropout 15%
Park et al. (2009)⁴⁵	38	Retrospective trial	TU 1000 mg IM or testosterone gel for 18 weeks	ED, non-responder to PDE5 inhibitor350 ng dl⁻¹	IIEF	—	—	No adverse eventNo dropout

Abbreviations: ADAM: Androgen Deficiency in Aging Men; AMS: Aging Male Symptoms Scale; ED: erectile dysfunction; FT: free testosterone; GEQ: global efficacy question; IIEF: International Index of Erectile Function; IPSS: International Prostate Symptom Score; LOH: late-onset hypogonadism; PDE5, phosphodiesterase type 5; PNUHQoL: Pusan National University Quality of Life Scoring System; RIA: radioimmunoassay; T: serum testosterone; TU: testosterone undecanoate.